Ask the Scholar
Page 2 of 5
I can add historical knowledge about this page.
Page image
OCR
- 2 -
HEW-C15
The vaccine manufactured by the Cutter Laboratories had been used in all
but 3 of these cases.
In releasing the latest tabulation, the Surgeon General pointed out that
as of the present moment this represented a total of only 29 cases.
Approximately 4 million children have been vaccinated.
"It is important to remember, Dr. Scheele said, "that the field trials of
the vaccine indicated that it was from 60 to 90 percent effective. It must be
anticipated that additional cases will inevitably occur among some of those for
whom the vaccine is not effective."
The Surgeon General reiterated the belief of the Service that the mass
inoculations now under way ghould be continued.
It was emphasized in the advisory group;s report that at the present time
there is no reason to suggest that vaccine of manufacturers other than Cutter
should be withheld.
The
A summary of the recommendations follows:
NEY
The consultants agreed that the data presented on reported cases of
paralysis following infection with vaccine manufactured by the Cutter Laboratories
justify the action of the Public Health Service in ordering discontinuance of the
use of Cutter vaccine pending necessary investigations.
The group said that the failure of significant numbers of cases to occur
following the administration of vaccine prepared by manufacturers other than
Cutter warrants the continuation of vaccination with products prepared by other
manufacturers.
The group's discussion of the Cutter vaccine centered around three basic
questions, upon which continuing studies were recommended:
(More)
Page data
- Page
- 2
- Source index
- 0
- Type
- photo
- Media ID
- 0fbed809f0403a66
- Size
- unknown
Document data
- ID
- 12166299
- Core
- doc
- Type
- document
DTO data
{
"id": "12166299",
"sourceUrl": "https://catalog.archives.gov/id/12166299",
"contentType": "document",
"title": "Press Release Regarding the Cutter Laboratory Vaccine",
"citationUrl": "https://catalog.archives.gov/id/12166299",
"collections": [
"Oveta Culp Hobby Papers",
"Personal Files"
],
"iiifBase": "https://s3.amazonaws.com/NARAprodstorage/lz/presidential-libraries/eisenhower/582312/582312_002_Page_1.jpg",
"thumbnailUrl": "https://s3.amazonaws.com/NARAprodstorage/lz/presidential-libraries/eisenhower/582312/582312_002_Page_1.jpg",
"largeImageUrl": "https://s3.amazonaws.com/NARAprodstorage/lz/presidential-libraries/eisenhower/582312/582312_002_Page_1.jpg",
"imageCount": 5,
"hasImages": true,
"source": "import",
"hasTranscription": false
}
Context sent to Scholar
Document identity
{
"localId": "12166299",
"label": "Press Release Regarding the Cutter Laboratory Vaccine",
"core": "doc",
"dtoType": "document",
"citationUrl": "https://catalog.archives.gov/id/12166299"
}
Document source metadata
{
"id": "12166299",
"sourceUrl": "https://catalog.archives.gov/id/12166299",
"contentType": "document",
"title": "Press Release Regarding the Cutter Laboratory Vaccine",
"citationUrl": "https://catalog.archives.gov/id/12166299",
"collections": [
"Oveta Culp Hobby Papers",
"Personal Files"
],
"iiifBase": "https://s3.amazonaws.com/NARAprodstorage/lz/presidential-libraries/eisenhower/582312/582312_002_Page_1.jpg",
"thumbnailUrl": "https://s3.amazonaws.com/NARAprodstorage/lz/presidential-libraries/eisenhower/582312/582312_002_Page_1.jpg",
"largeImageUrl": "https://s3.amazonaws.com/NARAprodstorage/lz/presidential-libraries/eisenhower/582312/582312_002_Page_1.jpg",
"imageCount": 5,
"hasImages": true,
"source": "import",
"hasTranscription": false
}
Document source extras
{
"url": "https://catalog.archives.gov/id/12166299",
"naId": 12166299,
"levelOfDescription": "item",
"productionDates": [
{
"day": 30,
"logicalDate": "1955-04-30",
"month": 4,
"year": 1955
}
],
"recordType": "description",
"ocrSource": "nara-archive"
}
Page context
{
"seq": 2,
"pageIndex": 0,
"type": "photo",
"url": "https://s3.amazonaws.com/NARAprodstorage/lz/presidential-libraries/eisenhower/582312/582312_002_Page_2.jpg",
"mediaId": "0fbed809f0403a66",
"ocrText": "- 2 -\nHEW-C15\nThe vaccine manufactured by the Cutter Laboratories had been used in all\nbut 3 of these cases.\nIn releasing the latest tabulation, the Surgeon General pointed out that\nas of the present moment this represented a total of only 29 cases.\nApproximately 4 million children have been vaccinated.\n\"It is important to remember, Dr. Scheele said, \"that the field trials of\nthe vaccine indicated that it was from 60 to 90 percent effective. It must be\nanticipated that additional cases will inevitably occur among some of those for\nwhom the vaccine is not effective.\"\nThe Surgeon General reiterated the belief of the Service that the mass\ninoculations now under way ghould be continued.\nIt was emphasized in the advisory group;s report that at the present time\nthere is no reason to suggest that vaccine of manufacturers other than Cutter\nshould be withheld.\nThe\nA summary of the recommendations follows:\nNEY\nThe consultants agreed that the data presented on reported cases of\nparalysis following infection with vaccine manufactured by the Cutter Laboratories\njustify the action of the Public Health Service in ordering discontinuance of the\nuse of Cutter vaccine pending necessary investigations.\nThe group said that the failure of significant numbers of cases to occur\nfollowing the administration of vaccine prepared by manufacturers other than\nCutter warrants the continuation of vaccination with products prepared by other\nmanufacturers.\nThe group's discussion of the Cutter vaccine centered around three basic\nquestions, upon which continuing studies were recommended:\n(More)"
}